Sugi Predict

Sugi Predict / Compounds / SCHEMBL216323

SCHEMBL216323

SCHEMBL216323

CC(C)(C)OC(=O)N1CCCC(c2cccs2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGDS O60760 1/20 0.48
▸ GPR119 Q8TDV5 2/20 0.46
▸ USP30 Q70CQ3 1/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ CASP1 P29466 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ FEN1 P39748 1/20 0.45
▸ ACKR3 P25106 1/20 0.45
▸ JAK2 O60674 1/20 0.45
▸ JAK1 P23458 1/20 0.45
▸ BRD4 O60885 2/20 0.44
▸ BRDT Q58F21 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30114532 0.94 GPR119 (0.49) HPGDSGPR119USP30MEN1ALDH1A1
SCHEMBL3649642 0.94 GPR119 (0.49) HPGDSGPR119USP30MEN1ALDH1A1
SCHEMBL985065 0.87 GPR119 (0.55) GPR119ALDH1A1MAPTKDM4EBRD4
SCHEMBL21193363 0.81 HPGDS (0.47) HPGDSGPR119USP30MEN1ALDH1A1
SCHEMBL22815189 0.81 BRD4 (0.60) GPR119USP30MEN1ALDH1A1MAPT
SCHEMBL31283582 0.81 GPR119 (0.47) GPR119USP30MEN1ALDH1A1MAPT
SCHEMBL6359096 0.79 ALDH1A1 (0.56) HPGDSGPR119USP30ALDH1A1MAPT
SCHEMBL30100991 0.78 ALDH1A1 (0.44) GPR119USP30MEN1ALDH1A1MAPT
SCHEMBL16640404 0.78 MAPK1 (0.44) GPR119USP30MEN1ALDH1A1MAPT
SCHEMBL30100978 0.78 USP2 (0.43) GPR119USP30MEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8624033-B2 Pleuromutilins and process for the preparation of pleuromutilins NABRIVA THERAPEUTICS AG (AT) 2014-01-07 — — US disclosed
US-20130053571-A1 PLEUROMUTILINS AND PROCESS FOR THE PREPARATION OF PLEUROMUTILINS NABRIVA THERAPEUTICS AG (AT) 2013-02-28 — — US disclosed
US-8334389-B2 Process for the preparation of pleuromutilins NABRIVA THERAPEUTICS AG (AT) 2012-12-18 — — US disclosed
US-20120046276-A1 Tuberculosis treatment using pleuromutilin derivatives NABRIVA THERAPEUTICS AG (AT) 2012-02-23 — — US disclosed
US-8088823-B2 Tuberculosis treatment using pleuromutilin derivatives NABRIVA THERAPEUTICS AG (AT) 2012-01-03 — — US disclosed
EP-2069301-B1 PROCESS FOR THE PREPARATION OF PLEUROMUTILINS NABRIVA THERAPEUTICS AG (AT) 2011-09-07 — — EP disclosed
EP-2272829-A2 Process for the preparation of pleuromutilins Nabriva Therapeutics AG (AT) 2011-01-12 — — EP disclosed
EP-1501495-B1 USE OF PLEUROMUTILINS FOR THE TREATMENT OF DISORDERS CAUSED BY HELICOBACTER PYLORI NABRIVA THERAPEUTICS AG (AT) 2010-09-08 — — EP disclosed
US-7790749-B2 Use of pleuromutilins for the treatment of disorders caused by Helicobacter pylori NABRIVA THERAPEUTICS AG (AT) 2010-09-07 — — US disclosed
EP-1875903-B1 TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES NABRIVA THERAPEUTICS AG (AT) 2010-07-28 — — EP disclosed
WO-2008040043-A1 PROCESS FOR THE PREPARATION OF PLEUROMUTILINS NABRIVA THERAPEUTICS AG (AT) 2008-04-10 — — WO disclosed
EP-1908750-A1 Process for the preparation of pleuromutilins Nabriva Therapeutics Forschungs GmbH (AT) 2008-04-09 — — EP disclosed
EP-1875903-A1 TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES Nabriva Therapeutics Forschungs GmbH (AT) 2008-01-09 — — EP disclosed
US-20070270404-A1 Tuberculosis treatment using pleuromutilin derivatives NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) 2007-11-22 — — US disclosed
US-20050215637-A1 Tuberculosis treatment ASCHER GERD 2005-09-29 — — US disclosed
US-20050131023-A1 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) 2005-06-16 — — US disclosed
EP-1501495-A1 USE OF PLEUROMUTILINS FOR THE TREATMENT OF DISORDERS CAUSED BY HELICOBACTER PYLORI Sandoz AG (CH) 2005-02-02 — — EP disclosed
EP-1492518-A2 TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES Sandoz AG (CH) 2005-01-05 — — EP disclosed
WO-2003090740-A1 USE OF PLEUROMUTILINS FOR THE TREATMENT OF DISORDERS CAUSED BY HELICOBACTER PYLORI SANDOZ AG (CH) 2003-11-06 — — WO disclosed
WO-2003082260-A2 TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES SANDOZ AG (CH) 2003-10-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131023-A1 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori FABP6, PLEC, UBQLN2 HPGDS 34/4885GPR119 1915/4885USP30 128/4885
US-20050215637-A1 Tuberculosis treatment TTR, TST, TREH HPGDS 856/4885GPR119 3952/4885USP30 711/4885
US-20130053571-A1 PLEUROMUTILINS AND PROCESS FOR THE PREPARATION OF PLEUROMUTILINS PLEC, MLN, PTMA HPGDS 3490/4885GPR119 3056/4885USP30 508/4885
US-20070270404-A1 Tuberculosis treatment using pleuromutilin derivatives PLEC, TTR, TREH HPGDS 743/4885GPR119 3802/4885USP30 446/4885
US-20120046276-A1 Tuberculosis treatment using pleuromutilin derivatives PLEC, TTR, TREH HPGDS 743/4885GPR119 3802/4885USP30 446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.